Evidence map›Paper›PMID 35078830›Full record

ArticleBMJ open2022

Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection (BATCH): protocol for a randomised controlled trial.

Cherry-Ann Waldron, Emma Thomas-Jones, Jolanta Bernatoniene, Lucy Brookes-Howell, Saul N Faust, Debbie Harris, Lucy Hinds, Kerenza Hood, Chao Huang, Céu Mateus and 7 more

Open access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 10 institutions in 1 country.

Cherry-Ann WaldronCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK waldronc@cardiff.ac.uk.ORCID 0000-0001-8465-2492
Emma Thomas-JonesCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
Jolanta BernatonieneDepartment of Paediatric Infectious Disease and Immunology, Bristol Royal Hospital for Children, Bristol, UK.
Lucy Brookes-HowellCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
Saul N FaustNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton, University of Southampton NHS Foundation Trust, Southampton, UK.
Debbie HarrisCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
Lucy HindsDepartment of Paediatrics, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Kerenza HoodCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
Chao HuangHull York Medical School, University of Hull, Hull, UK.
Céu MateusDivision of Health Research, Lancaster University, Lancaster, UK.
Philip PallmannCentre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.ORCID 0000-0001-8274-9696
Sanjay PatelNIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton, University of Southampton NHS Foundation Trust, Southampton, UK.
Stéphane PaulusDepartment of Paediatrics, University of Oxford, Oxford, UK.ORCID 0000-0002-0703-9114
Matthew PeakAlder Hey Children's NHS Foundation Trust, Liverpool, UK.
Colin PowellDepartment of Paediatrics, Children's Hospital for Wales, Cardiff, UK.
Jennifer PrestonNIHR Alder Hey Clinical Research Facility, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK.
Enitan D CarrolInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK.
Cardiff University · GBUniversity Hospital Southampton NHS Foundation Trust · GBUniversity of Liverpool · GBAlder Hey Children's NHS Foundation Trust · GBBristol Royal Hospital for Children · GBLancaster University · GBNoah's Ark Children's Hospital for Wales · GBSheffield Children's NHS Foundation Trust · GBUniversity of Hull · GBUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionProcalcitonin (PCT) is a biomarker more specific for bacterial infection and responds quicker than other commonly used biomarkers such as C reactive protein, but is not routinely used in the National Health Service (NHS). Studies mainly in adults show that using PCT to guide clinicians may reduce antibiotic use, reduce hospital stay, with no associated adverse effects such as increased rates of hospital re-admission, incomplete treatment of infections, relapse or death. A review conducted for National Institute for Health and Care Excellence recommends further research on PCT testing to guide antibiotic use in children. METHODS AND ANALYSIS: Biomarker-guided duration of Antibiotic Treatment in Children Hospitalised with confirmed or suspected bacterial infection is a multi-centre, prospective, two-arm, individually Randomised Controlled Trial (RCT) with a 28-day follow-up and internal pilot. The intervention is a PCT-guided algorithm used in conjunction with best practice. The control arm is best practice alone. We plan to recruit 1942 children, aged between 72 hours and up to 18 years old, who are admitted to the hospital and being treated with intravenous antibiotics for suspected or confirmed bacterial infection. Coprimary outcomes are duration of antibiotic use and a composite safety measure. Secondary outcomes include time to switch from broad to narrow spectrum antibiotics, time to discharge, adverse drug reactions, health utility and cost-effectiveness. We will also perform a qualitative process evaluation. Recruitment commenced in June 2018 and paused briefly between March and May 2020 due to the COVID-19 pandemic. ETHICS AND DISSEMINATION: The trial protocol was approved by the HRA and NHS REC (North West Liverpool East REC reference 18/NW/0100). We will publish the results in international peer-reviewed journals and present at scientific meetings. TRIAL REGISTRATION NUMBER: ISRCTN11369832.

Indexed as

Bacterial InfectionsCOVID-19AdultAgedAnti-Bacterial AgentsBiomarkersChildHumansMulticenter Studies as TopicRandomized Controlled Trials as TopicSARS-CoV-2Anti-Bacterial AgentsBiomarkersdiagnostic microbiologyinfectious diseasespaediatric intensive & critical carepublic health

Identifiers

PMID35078830
PMCPMC8796242
OpenAlexW4207036796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.